Cargando…

Response to Treatment with an Anti-Interleukin-6 Receptor Antibody (Tocilizumab) in a Patient with Hemophagocytic Syndrome Secondary to Immune Checkpoint Inhibitors

Background. Immunotherapy represents one of the fundamental treatments in the management of some types of cancer, especially malignant melanoma. Toxicity derived from increased immune system activity can manifest in multiple organs and systems. We present a case of hematological toxicity, manifested...

Descripción completa

Detalles Bibliográficos
Autores principales:	Olivares-Hernández, Alejandro, Figuero-Pérez, Luis, Amores Martín, María A., Bellido Hernández, Lorena, Mezquita, Laura, Vidal Tocino, María del Rosario, López Cadenas, Félix, Gómez-Caminero López, Felipe, Escala-Cornejo, Roberto A., Cruz Hernández, Juan Jesús
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7895569/ https://www.ncbi.nlm.nih.gov/pubmed/33628551 http://dx.doi.org/10.1155/2021/6631859

Ejemplares similares

Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab()
por: Figuero-Pérez, Luis, et al.
Publicado: (2021)

Anakinra, una alternativa potencial en el tratamiento de la infección respiratoria grave por SARS-CoV-2 refractaria a tocilizumab
por: Figuero-Pérez, Luis, et al.
Publicado: (2021)

Uso de anakinra en el tratamiento de la infección respiratoria grave por SARS-CoV-2
por: Figuero-Pérez, Luis, et al.
Publicado: (2023)

Use of anakinra in the treatment of SARS-CoV-2 severe respiratory infection()
por: Figuero-Pérez, Luis, et al.
Publicado: (2023)

Influence of DNA Mismatch Repair (MMR) System in Survival and Response to Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC): Retrospective Analysis
por: Olivares-Hernández, Alejandro, et al.
Publicado: (2022)

Immune System Disorders, Cancer and Viral Infections: A New Treatment Opportunity for the Immune Checkpoint Inhibitors
por: Olivares-Hernández, Alejandro, et al.
Publicado: (2021)

Autoimmune Haemolytic Anaemia Due to Cold Antibodies in a Renal Cancer Patient
por: Terán Brage, Eduardo, et al.
Publicado: (2022)

Cardiotoxicity Secondary to Immune Checkpoint Inhibitors in the Elderly: Safety in Real-World Data
por: Toribio-García, Irene, et al.
Publicado: (2023)

Resistance to Immune Checkpoint Inhibitors Secondary to Myeloid-Derived Suppressor Cells: A New Therapeutic Targeting of Haematological Malignancies
por: Olivares-Hernández, Alejandro, et al.
Publicado: (2021)

Tocilizumab as a possible cause of ischemic colitis()
por: Forneiro Pérez, Rocío, et al.
Publicado: (2021)

Tocilizumab como posible causa de colitis isquémica
por: Forneiro Pérez, Rocío, et al.
Publicado: (2021)

Fulminant myocarditis in a patient with a lung adenocarcinoma after the third dose of modern COVID-19 vaccine. A case report and literature review
por: Terán Brage, Eduardo, et al.
Publicado: (2022)

IL6-R blocking with tocilizumab in critically ill patients with hemophagocytic syndrome
por: Dufranc, Etienne, et al.
Publicado: (2020)

Hemophagocytic lymphohistiocytosis in a patient with COVID-19 treated with tocilizumab: a case report
por: Tholin, Birgitte, et al.
Publicado: (2020)

Immune checkpoint inhibitors in non-small cell lung cancer: from current perspectives to future treatments—a systematic review
por: Olivares-Hernández, Alejandro, et al.
Publicado: (2023)

Hemophagocytic Lymphohistiocytosis Secondary to Immune Checkpoint Inhibitor Therapy
por: Rajapakse, Pramuditha, et al.
Publicado: (2022)

Limited efficacy of tocilizumab in adult patients with secondary hemophagocytic lymphohistiocytosis: a retrospective cohort study
por: Kim, Ju Yeon, et al.
Publicado: (2022)

Hemophagocytic Lymphohistiocytosis Associated with Immunological Checkpoint Inhibitors: A Pharmacovigilance Study
por: Diaz, Laurine, et al.
Publicado: (2023)

Helmet mask and tocilizumab for a patient with hemophagocytic lymphohistiocytosis syndrome and COVID-19: a case report
por: Eroglu, Ahmet, et al.
Publicado: (2020)

Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis
por: Doms, J., et al.
Publicado: (2020)

Soluble Interleukin-6 Receptor Regulates Interleukin-6-Dependent Vascular Remodeling in Long-Distance Runners
por: Villar-Fincheira, Paulina, et al.
Publicado: (2021)

Glucocorticoids alone versus tocilizumab alone or glucocorticoids plus tocilizumab in patients with severe SARS-CoV-2 pneumonia and mild inflammation()
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2021)

Date of Admission during COVID-19 Pandemic Impacted Patient Outcomes in Addition to the Higher Efficacy of Tocilizumab Plus High-Dose Corticosteroid Therapy Compared to Tocilizumab Alone
por: Belhassen-García, Moncef, et al.
Publicado: (2021)

Planeación operativa para el manejo de aparatos electromédicos en la unidad de cuidados intensivos en el H.G.Z No. 11
por: Amores Hernández, Virginia
Publicado: (1998)

A Potential New Use for Tocilizumab: Refractory Checkpoint Inhibitor Hepatitis
por: Lyles, Laine, et al.
Publicado: (2023)

Two cases of lung cancer with hemophagocytic lymphohistiocytosis caused by immune checkpoint inhibitors
por: Kurozumi, Atsumasa, et al.
Publicado: (2021)

Role of Interleukin-6 in Vascular Health and Disease
por: Villar-Fincheira, Paulina, et al.
Publicado: (2021)

Dopamine Receptors and the Kidney: An Overview of Health- and Pharmacological-Targeted Implications
por: Olivares-Hernández, Alejandro, et al.
Publicado: (2021)

Glucocorticoides solos versus tocilizumab solo o glucocorticoides más tocilizumab en pacientes con neumonía grave por SARS-CoV-2 e inflamación moderada
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2021)

Aspectos extrínsecos e intrínsecos que provocan el comportamiento maternal en Copris incertus, Say (Coleoptera, Scarabaeidae, Scarabaaeinae) /
por: López Hernández, María del Rosario
Publicado: (1997)

A Case Report of Immune Checkpoint Inhibitor-Induced Aortitis Treated with Tocilizumab
por: Bloomer, Chance H., et al.
Publicado: (2022)

Successful treatment of cytomegalovirus associated hemophagocytic lymphohistiocytosis with the interleukin 1 inhibitor – anakinra
por: Divithotawela, Chandima, et al.
Publicado: (2015)

American-Asian- and African lineages of Zika virus induce differential pro-inflammatory and Interleukin 27-dependent antiviral responses in human monocytes
por: Hernández-Sarmiento, Lady Johana, et al.
Publicado: (2023)

Encephalitis Associated With Hemophagocytic Lymphohistiocytosis Secondary to Immune Checkpoint Inhibitors: An Unfamiliar Spin-Off
por: Ghous, Ghulam, et al.
Publicado: (2021)

Immune Checkpoint Inhibitor-Induced Hemophagocytic Lymphohistiocytosis in a Patient With Squamous Cell Carcinoma
por: Marar, Rosalyn, et al.
Publicado: (2022)

566. Tocilizumab: A Friend or a Foe in COVID-19 Management?
por: Hernandez, Jarelys M, et al.
Publicado: (2020)

Comparative Effectiveness of Tocilizumab with either Methotrexate or Leflunomide in the Treatment of Rheumatoid Arthritis
por: Narváez, Javier, et al.
Publicado: (2015)

Interleukin-6 inhibition for treatment of rheumatoid arthritis: A review of tocilizumab therapy
por: Patel, Aarat M, et al.
Publicado: (2010)

Tocilizumab, a Proposed Therapy for the Cachexia of Interleukin6-Expressing Lung Cancer
por: Ando, Katsutoshi, et al.
Publicado: (2014)

Interleukin 6 levels after tocilizumab administration in transplant recipients with COVID-19
por: Gade, Akhil R., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_534kq4at82ftm3ipuuuci77qvi